Itocad 100 Injection contains Etoposide 20 mg/ml, a semisynthetic podophyllotoxin derivative used primarily as an antineoplastic agent. Itocad 100 is indicated for the treatment of various malignancies, including small cell lung cancer, testicular cancer, lymphomas, and acute myeloid leukemia. Etoposide acts by inhibiting the enzyme topoisomerase II, leading to DNA strand breaks and subsequent apoptosis of rapidly dividing cancer cells. The injection formulation allows for intravenous administration, ensuring rapid systemic bioavailability and precise dosing in clinical settings. Dosage and duration of therapy should be individualized based on tumor type, patient condition, and response to treatment, with careful monitoring for hematologic toxicity, including neutropenia and thrombocytopenia. Other adverse effects may include alopecia, mucositis, hypotension during infusion, and gastrointestinal disturbances. Itocad 100 Injection is contraindicated in patients with hypersensitivity to etoposide or any formulation components, and caution is advised in those with impaired hepatic or renal function. Due to its cytotoxic nature, appropriate handling and administration protocols must be followed to minimize exposure risks to healthcare personnel. Regular blood counts and clinical assessments are essential to optimize therapeutic outcomes and manage potential toxicities during treatment with Itocad 100 Injection.